ZA201001580B - Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent - Google Patents

Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent

Info

Publication number
ZA201001580B
ZA201001580B ZA2010/01580A ZA201001580A ZA201001580B ZA 201001580 B ZA201001580 B ZA 201001580B ZA 2010/01580 A ZA2010/01580 A ZA 2010/01580A ZA 201001580 A ZA201001580 A ZA 201001580A ZA 201001580 B ZA201001580 B ZA 201001580B
Authority
ZA
South Africa
Prior art keywords
pancreatic cancer
combination therapy
chemotherapeutic agent
antigenic peptide
antigenic
Prior art date
Application number
ZA2010/01580A
Other languages
English (en)
Inventor
Hiroki Yamaue
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of ZA201001580B publication Critical patent/ZA201001580B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ZA2010/01580A 2007-08-24 2010-03-04 Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent ZA201001580B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95792307P 2007-08-24 2007-08-24
PCT/JP2008/002232 WO2009028150A1 (en) 2007-08-24 2008-08-19 Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent

Publications (1)

Publication Number Publication Date
ZA201001580B true ZA201001580B (en) 2011-02-23

Family

ID=40386893

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/01580A ZA201001580B (en) 2007-08-24 2010-03-04 Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent

Country Status (19)

Country Link
US (1) US8703713B2 (enExample)
EP (1) EP2195003A4 (enExample)
JP (1) JP5417667B2 (enExample)
KR (1) KR20100047899A (enExample)
CN (1) CN101883577A (enExample)
AR (1) AR068020A1 (enExample)
AU (1) AU2008292966C1 (enExample)
BR (1) BRPI0815726A2 (enExample)
CA (1) CA2697501A1 (enExample)
IL (1) IL204143A (enExample)
MX (1) MX2010002178A (enExample)
MY (1) MY160406A (enExample)
NZ (1) NZ583578A (enExample)
RU (1) RU2472522C2 (enExample)
SG (1) SG183770A1 (enExample)
TW (1) TWI436775B (enExample)
UA (1) UA100702C2 (enExample)
WO (1) WO2009028150A1 (enExample)
ZA (1) ZA201001580B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2261249T3 (en) 2002-09-12 2015-02-16 Oncotherapy Science Inc KDR peptides and vaccines comprising the same
US20080034017A1 (en) * 2006-08-04 2008-02-07 Dominic Giampaolo Links to a common item in a data structure
TW201109029A (en) * 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
EP2578233B1 (en) * 2010-05-28 2017-04-26 National Cancer Center Therapeutic agent for pancreatic cancer
DE102013214023B4 (de) * 2013-07-17 2015-02-12 Siemens Aktiengesellschaft Verfahren zu einem Auswerten und Vergleichen von zeitlich aufeinander folgenden kombinierten medizinischen Bildgebungsuntersuchungen sowie ein medizinisches Bildgebungssystem, das zu einem Ausführen des erfindungsgemäßen Verfahrens ausgelegt ist
DK3597742T3 (da) * 2014-10-09 2022-10-03 Univ Yamaguchi Car-udtrykkende vektor og car-udtrykkende t-celler
JP6613312B2 (ja) * 2014-10-14 2019-11-27 ジ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンティッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシズ 膵臓癌を処置するためのペプチドをベースとする方法
JP7168228B2 (ja) * 2017-05-19 2022-11-09 慶應義塾 脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物
US10413584B1 (en) 2018-08-29 2019-09-17 Riptide Bioscience, Inc. Peptides having immunomodulatory properties
US10548944B1 (en) 2018-10-19 2020-02-04 Riptide Bioscience, Inc. Antimicrobial peptides and methods of using the same
CA3134420A1 (en) 2019-04-12 2020-10-15 Riptide Bioscience, Inc. Methods for modulating macrophage activity
CN114959031A (zh) * 2022-05-20 2022-08-30 上海交通大学医学院附属瑞金医院 胰腺腺癌预后评估的标志物组合及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB213645A (en) 1922-12-22 1924-03-24 Frank Lincoln Morse Improvements in and relating to chain and sprocket wheel gearing
US3265572A (en) 1961-09-20 1966-08-09 S B Penick And Company Process for preparing tyrociding and product produced thereby
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
WO1994021679A1 (en) 1993-03-25 1994-09-29 Merck & Co., Inc. Inhibitor of vascular endothelial cell growth factor
US6080728A (en) 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
WO1998031794A1 (fr) 1997-01-17 1998-07-23 Toa Gosei Co., Ltd. Polypeptide liant le facteur vegf
WO1999040118A1 (en) 1998-02-04 1999-08-12 Kyowa Hakko Kogyo Co., Ltd. Antibodies against human vegf receptor kdr
GB9804121D0 (en) 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
EP1086705A4 (en) 1998-05-20 2002-02-06 Kyowa Hakko Kogyo Kk INHIBITORS OF THE ACTIVITY OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
DK2261249T3 (en) 2002-09-12 2015-02-16 Oncotherapy Science Inc KDR peptides and vaccines comprising the same
US7265096B2 (en) 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
ATE507240T1 (de) * 2004-03-05 2011-05-15 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
KR100986945B1 (ko) * 2004-06-03 2010-10-12 에프. 호프만-라 로슈 아게 젬시타빈 및 ｅｇｆｒ-억제제로의 치료
PL1831237T3 (pl) 2004-12-17 2009-01-30 Lilly Co Eli Amidowy prolek gemcytabiny, kompozycje go zawierające oraz jego zastosowanie
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
PL2119447T3 (pl) 2007-02-16 2013-08-30 Oncotherapy Science Inc Terapia szczepionkowa przeciwko neowaskularyzacji naczyniówkowej

Also Published As

Publication number Publication date
WO2009028150A1 (en) 2009-03-05
KR20100047899A (ko) 2010-05-10
SG183770A1 (en) 2012-09-27
NZ583578A (en) 2012-07-27
BRPI0815726A2 (pt) 2016-01-05
UA100702C2 (ru) 2013-01-25
EP2195003A4 (en) 2011-07-06
TWI436775B (zh) 2014-05-11
CA2697501A1 (en) 2009-03-05
AU2008292966C1 (en) 2013-03-14
JP5417667B2 (ja) 2014-02-19
JP2010536714A (ja) 2010-12-02
MY160406A (en) 2017-03-15
AU2008292966A1 (en) 2009-03-05
AR068020A1 (es) 2009-10-28
US20110082088A1 (en) 2011-04-07
TW200914037A (en) 2009-04-01
RU2010111139A (ru) 2011-09-27
MX2010002178A (es) 2010-03-18
RU2472522C2 (ru) 2013-01-20
EP2195003A1 (en) 2010-06-16
AU2008292966B2 (en) 2012-07-19
IL204143A (en) 2013-04-30
US8703713B2 (en) 2014-04-22
CN101883577A (zh) 2010-11-10

Similar Documents

Publication Publication Date Title
EP2195003A4 (en) COMBINATION THERAPY AGAINST PANCREATIC CANCER WITH AN ANTIGEN PEPTIDE AND CHEMOTHERAPEUTIC
IL195371A0 (en) Mobile radiation therapy
IL197389A0 (en) Prophylactic or therapeutic agent for cancer
ZA200905886B (en) Methods and kits for administering probiotics
IL185908A0 (en) Therapeutic agent for dyskinesia
IL193710A0 (en) CANCER TREATMENT COMBINING LYMPHODEPLETING AGENT WITH CTLs AND CYTOKINES
EP2025347A4 (en) PROPHYLACTIC AND THERAPEUTIC AGENTS AGAINST CANCER
IL197727A0 (en) Combination treatment of cd38-expressing tumors
PT2101731T (pt) Endoxifeno para utilização no tratamento de cancro
EP2148685A4 (en) METHODS AND COMPOUNDS FOR THERAPY BASED ON VITAMIN D
IL194826A0 (en) Compositions and methods for cellular imaging and therapy
EP2004637A4 (en) SUBSTITUTED RING-CONDENSED AZINES AND THEIR USE IN CANCER THERAPY
EP2004154A4 (en) THERAPEUTIC BELT
GB0519405D0 (en) Cancer therapy prognosis and target
EP2144887A4 (en) PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
IL178920A0 (en) Treatment for pancreatic cancer
IL199911A0 (en) 3-cinnolinecarboxamide derivatives and their use for treating cancer
EP1841467A4 (en) COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES
EP2236148A4 (en) MEDIinic agent for HELICOBACTER treatment
GB0607946D0 (en) Mono and combination therapy
GB0607949D0 (en) Mono and combination therapy
GB0625481D0 (en) Detector apparatus and pre-concentrators
GB0609121D0 (en) Peptide Therapy
IL192738A0 (en) Compounds and methods for the treatment of cancer
HK1140148A (en) Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent